Article Text

Download PDFPDF

001 Multiparametric mapping to understand pathophysiology in cardiac amyloidosis
  1. Tushar Kotecha1,
  2. Ana Martinez-Naharro1,
  3. Thomas A Treibel2,
  4. Rohin Francis1,
  5. Sabrina Nordin2,
  6. Amna Abdel-Gadir2,
  7. Daniel S Knight1,
  8. Giulia Zumbo1,
  9. Stefania Rosmini2,
  10. Viviana Maestrini2,
  11. Heerajnarain Bulluck2,
  12. Roby Rakhit1,
  13. Ashutosh D Wechalekar1,
  14. Peter Kellman3,
  15. Julian D Gillmore1,
  16. James C Moon2,
  17. Philip N Hawkins1,
  18. Marianna Fontana1
  1. 1Royal Free Hospital, London, UK
  2. 2Barts Heart Centre, London, UK
  3. 3National Heart, Lung and Blood Institute, USA


Background The prognosis and treatment of the 2 main types of cardiac amyloidosis, immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis are substantially influenced by cardiac involvement. ATTR amyloidosis has better prognosis than AL despite more amyloid infiltration. This paradox suggests additional mechanisms of damage in AL amyloidosis. The aim of this study was to assess the presence and ?prognostic significance of oedema in a large population of patients with cardiac amyloidosis and compare findings among those with TTR and AL types.

Methods and results 286 patients (100 with systemic AL amyloidosis (including 49 patients scanned prior to commencing chemotherapy), 163 with cardiac ATTR amyloidosis, 12 with suspected cardiac ATTR amyloidosis (grade 1 on 99mTc-DPD) and 11 asymptomatic individuals with amyloidogenic transthyretin(TTR) mutations), and 30 healthy volunteers were recruited. All subjects underwent CMR with T1 and T2 mapping, and ECV quantification. Left ventricular(LV) mass and ECV were higher in ATTR compared to AL whilst LV ejection fraction(EF) was significantly lower(p<0.001). There was no significant difference in ECV between treated and untreated AL (Figure 1a). T2 was increased in cardiac amyloidosis compared to healthy volunteers with the degree of elevation being the highest in untreated AL patients (T2: 56.3±4.9 ms AL untreated, 54.0 ±4.5 ms AL treated, 54.3±4.1 ms ATTR, 48.9±2.0 ms controls, p<0.05 for all except treated AL vs ATTR) (Figure 1b). During follow up (22.8±14.7 months), 75 (28% of AL group and 25% of ATTR group) patients died. Using Cox regression models, T2 predicted death in AL amyloidosis (hazard ratio, HR,1.48, 95% CI 1.20–1.82) and remained significant after adjusting for EF and ECV (HR 1.31, 95% CI 1.04–1.66) (Abstract 1 Figure 2).

Abstract 001 Figure 1

a. Mean ECV in cardiac AL (treated and untreated patients) and ATTR amyloidosis compared to healthy volunteers. b. Mean T2 in cardiac AL (treated and untreated patients) and ATTR amyloidosis compared to healthy volunteers.

Abstract 001 Figure 2

a. Examples of two patients with AL amyloidosis and transmural late gadolinium enhancement, one with eleveted T2 (top) and the other with normal T2 (bottom). b. Kaplan-Meier survival curve of patients with AL amyloidosis with high T2 and normal T2 values.

Conclusion Patients with AL amyloidosis have a worse prognosis compared to ATTR despite having less cardiac amyloid infiltration. T2 was significantly higher in untreated AL amyloidosis consistent with oedema, and was an independent predictor of prognosis. The higher ECV in ATTR was consistent with higher amyloid infiltration. These findings highlight the unique role of CMR with multiparametric mapping for characterising the cardiac effects of systemic amyloidosis and risk stratification in this population.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.